Single-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.
7 affiliations
- 1Vinmec-VinUni Institute of Immunology - College of Health Sciences - VinUniversity - Vinhomes Ocean Park, Gia Lam, Hanoi, Vietnam.
- 2Innovations in Health Sciences, VinUniversity, Hanoi, Vietnam.
- 3Department of Medical Genetics and Rare Diseases, Vinmec Times City International Hospital - Vinmec Healthcare System, 458 Minh Khai, Hai Ba Trung, Vinh Tuy, Hanoi, Vietnam.
- 4Centre of Allergy and Clinical Immunology, Bach Mai Hospital, Hanoi, Vietnam.
- 5Vinmec-VinUni Institute of Immunology - College of Health Sciences - VinUniversity - Vinhomes Ocean Park, Gia Lam, Hanoi, Vietnam. [email protected].
- 6Innovations in Health Sciences, VinUniversity, Hanoi, Vietnam. [email protected].
- 7Centre of Allergy and Clinical Immunology - Vinmec Times, City International Hospital - Vinmec Healthcare System, 458 Minh Khai, Hai Ba Trung, Vinh Tuy, Hanoi, Vietnam. [email protected].
Abstract
Autoimmune diseases are characterized by loss of immune tolerance and substantial heterogeneity across patients, tissues, and disease stages. Although bulk transcriptomic studies have identified important inflammatory pathways, they cannot directly resolve rare, transitional, and tissue-contextualized cell states that may be relevant to disease mechanisms and therapeutic response. Single-cell RNA sequencing (scRNA-seq) enables transcriptomic profiling at cellular resolution, while complementary multimodal, receptor-repertoire, epigenomic, and spatial approaches can link cellular states to protein phenotype, clonal architecture, regulatory programs, and tissue context. This review critically examines recent single-cell studies in rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, type 1 diabetes, and multiple sclerosis. Rather than providing a descriptive catalogue of published studies, we assess the strength of available evidence by distinguishing independently replicated findings from observations supported by limited studies, and cross-sectional associations from longitudinal, treatment-response, and functional evidence. Across the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain. We evaluate the translational potential of scRNA-seq for biomarker discovery, patient stratification, and treatment response prediction, while considering evidence from related tissue-based molecular stratification approaches, including the R4RA randomized trial in rheumatoid arthritis. R4RA provides prospective randomized evidence that synovial molecular features can enrich for differential therapeutic responses, but its use of bulk synovial transcriptomics and histopathology does not constitute prospective validation of single-cell-derived biomarkers. We further highlight cohort biases, reproducibility challenges, dissociation artifacts, computational ambiguity, and privacy concerns that constrain immediate clinical implementation. Together, these advances position single-cell profiling as a mechanistic discovery platform with substantial translational promise, contingent on standardization, validation across diverse cohorts, and integration with functional perturbation approaches.
Related
- Panax ginseng Across the Cardiovascular Continuum: Molecular Targets, Mechanistic Convergence, and Translational Challenges
- RNA therapeutics in rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis: a compartment-aware translational framework
- Dynamic three-dimensional chromatin remodeling in lung disease: mechanistic principles, pathogenic regulatory networks, and translational challenges
- Applying Spatial Transcriptomics to the Human Heart: A Practical Guide for Translational Studies.
- Natural Products in Anticancer Activity: 2nd Edition—From Chemical Diversity to Mechanistic and Translational Insights
BibTeX
@article{nguyen2026singlecell,
title = {{Single-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.}},
author = {Thanh-Hong Nguyen and Tuan-Dinh Nguyen and Oanh-Thi Hoang and Thuy-Thu T Can and Minh-Huyen T Nguyen and Mai-Hoang Tran and Hieu-Chi Chu and Dinh-Van Nguyen},
journal = {Clinical reviews in allergy \& immunology},
year = {2026},
month = oct,
doi = {10.1007/s12016-026-09211-0},
url = {https://europepmc.org/article/MED/42873393},
note = {CC BY},
}
RIS
TY - JOUR
TI - Single-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.
AU - Thanh-Hong Nguyen
AU - Tuan-Dinh Nguyen
AU - Oanh-Thi Hoang
AU - Thuy-Thu T Can
AU - Minh-Huyen T Nguyen
AU - Mai-Hoang Tran
AU - Hieu-Chi Chu
AU - Dinh-Van Nguyen
PY - 2026
DA - 2026/10/14
JO - Clinical reviews in allergy & immunology
DO - 10.1007/s12016-026-09211-0
UR - https://europepmc.org/article/MED/42873393
AB - Autoimmune diseases are characterized by loss of immune tolerance and substantial heterogeneity across patients, tissues, and disease stages. Although bulk transcriptomic studies have identified important inflammatory pathways, they cannot directly resolve rare, transitional, and tissue-contextualized cell states that may be relevant to disease mechanisms and therapeutic response. Single-cell RNA sequencing (scRNA-seq) enables transcriptomic profiling at cellular resolution, while complementary multimodal, receptor-repertoire, epigenomic, and spatial approaches can link cellular states to protein phenotype, clonal architecture, regulatory programs, and tissue context. This review critically examines recent single-cell studies in rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, type 1 diabetes, and multiple sclerosis. Rather than providing a descriptive catalogue of published studies, we assess the strength of available evidence by distinguishing independently replicated findings from observations supported by limited studies, and cross-sectional associations from longitudinal, treatment-response, and functional evidence. Across the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain. We evaluate the translational potential of scRNA-seq for biomarker discovery, patient stratification, and treatment response prediction, while considering evidence from related tissue-based molecular stratification approaches, including the R4RA randomized trial in rheumatoid arthritis. R4RA provides prospective randomized evidence that synovial molecular features can enrich for differential therapeutic responses, but its use of bulk synovial transcriptomics and histopathology does not constitute prospective validation of single-cell-derived biomarkers. We further highlight cohort biases, reproducibility challenges, dissociation artifacts, computational ambiguity, and privacy concerns that constrain immediate clinical implementation. Together, these advances position single-cell profiling as a mechanistic discovery platform with substantial translational promise, contingent on standardization, validation across diverse cohorts, and integration with functional perturbation approaches.
SN - 1080-0549
SN - 1559-0267
ER -